These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 12041787

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Interaction with CEP-1 beta-lactamase of RU 51746-2, the active form of the new oral cephalosporin RU 51807.
    Dusi C, Mistretta M, Cornaglia G, Fontana R.
    J Chemother; 1991 Jan; 3 Suppl 1():54-6. PubMed ID: 12041786
    [Abstract] [Full Text] [Related]

  • 3. PBP binding and periplasmic concentration as determinants of the antibacterial activities of three new oral cephalosporins in Escherichia coli.
    Cornaglia G, Ligozzi M, Bauernfeind A, Satta G, Fontana R.
    New Microbiol; 1994 Jul; 17(3):203-10. PubMed ID: 7968655
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of mecillinam and amoxicillin/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal beta-lactamases.
    Marre R, Schulz E.
    Arzneimittelforschung; 1988 Jul; 38(7):863-5. PubMed ID: 3061383
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. II. Stability to beta-lactamases and affinity for penicillin-binding proteins.
    Markus A, Klesel N, Wollmann T, Isert D, Limbert M, Schrinner E, Seibert G, Bauernfeind A, Jungwirth R, Wilhelm R.
    J Antibiot (Tokyo); 1992 Apr; 45(4):521-6. PubMed ID: 1592684
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR, Hujer AM, Helfand MS, Bonomo RA.
    FEMS Microbiol Lett; 2004 May 01; 234(1):99-103. PubMed ID: 15109726
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    Pitout JD, Le P, Church DL, Gregson DB, Laupland KB.
    Int J Antimicrob Agents; 2008 Oct 01; 32(4):333-8. PubMed ID: 18701262
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
    Rodriguez-Villalobos H, Malaviolle V, Frankard J, de Mendonça R, Nonhoff C, Struelens MJ.
    J Antimicrob Chemother; 2006 Apr 01; 57(4):771-4. PubMed ID: 16501056
    [Abstract] [Full Text] [Related]

  • 14. In vitro antimicrobial activity and beta-lactamase stability of moxalactam, a new 1-oxa-cephalosporin.
    Blandino G, Speciale A, Torrisi A, Russo G.
    Chemioterapia; 1984 Apr 01; 3(2):108-15. PubMed ID: 6335837
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R.
    Pharmacotherapy; 2008 Mar 01; 28(3):295-300. PubMed ID: 18294108
    [Abstract] [Full Text] [Related]

  • 16. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.
    Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M, Walsh TR, Sundsfjord A, Norwegian ESBL Study Group.
    J Clin Microbiol; 2007 Jan 01; 45(1):199-205. PubMed ID: 17079502
    [Abstract] [Full Text] [Related]

  • 17. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
    Sorlózano A, Gutiérrez J, Romero JM, de Dios Luna J, Damas M, Piédrola G.
    J Basic Microbiol; 2007 Oct 01; 47(5):413-6. PubMed ID: 17910106
    [Abstract] [Full Text] [Related]

  • 18. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, Vila J, Garau J.
    J Antimicrob Chemother; 2006 Apr 01; 57(4):780-3. PubMed ID: 16492721
    [Abstract] [Full Text] [Related]

  • 19. Investigation of extended-spectrum beta-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli in Korea.
    Jeong SH, Bae IK, Kwon SB, Lee JH, Jung HI, Song JS, Jeong BC, Kim SJ, Lee SH.
    Lett Appl Microbiol; 2004 Apr 01; 39(1):41-7. PubMed ID: 15189286
    [Abstract] [Full Text] [Related]

  • 20. Defining an extended-spectrum beta-lactamase.
    Livermore DM.
    Clin Microbiol Infect; 2008 Jan 01; 14 Suppl 1():3-10. PubMed ID: 18154524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.